Peptide LibraryPeptide Guides
Peptides for Men: What Each Category Is Actually Studied For
The peptides marketed to men span five unrelated categories, and the evidence quality between them varies more than the marketing suggests.
Peptide Library Editorial · October 22, 2026 · Updated October 30, 2026 · 3 min read
“Peptides for men” is a marketing category, not a pharmacological one. The compounds sold under it span five unrelated mechanisms, and the evidence behind them ranges from approved drugs with full labels to compounds that have never been given to a human under study conditions.
Sorting them by mechanism makes the difference visible.
1. Hormonal axis
Compound | Mechanism | Status |
|---|---|---|
Kisspeptin-10 | Upstream stimulus to GnRH release | Research; human studies exist |
Gonadorelin | GnRH itself | Approved in some forms |
Enclomiphene | SERM — not a peptide | Not approved as a standalone |
hCG | LH-like activity | Approved for specific indications |
This is the category with genuine recent human data. Chronic subcutaneous kisspeptin-10 has been shown to stimulate gonadotropin secretion over twelve days in healthy men, and a 2025 meta-analysis examined clomiphene and enclomiphene for male hypogonadism.
Hormonal axis manipulation is the category where self-experimentation carries the clearest risk. The HPG axis is a feedback system — intervening at one point changes the others, and the effects on fertility, endogenous production and downstream hormones are not observable without bloodwork. This is a category for a clinician and a lab panel, not a vial.
Covered in more depth in the peptides for testosterone guide.
2. Growth hormone axis
Compound | Mechanism | Status |
|---|---|---|
Tesamorelin | GHRH analogue | Approved — HIV-associated lipodystrophy only |
Sermorelin | GHRH 1-29 | Formerly approved; withdrawn from US market |
CJC-1295 | Long-acting GHRH analogue | Never approved |
Ipamorelin | Selective GH secretagogue | Never approved |
MK-677 | Oral GH secretagogue — not a peptide | Never approved |
Tesamorelin is the only one with a current US approval, and its indication is narrow and specific. The distinction between GHRH analogues and GH secretagogues is covered in ipamorelin vs sermorelin.
3. Metabolic
Compound | Mechanism | Status |
|---|---|---|
Semaglutide | GLP-1 agonist | Approved |
Tirzepatide | GIP/GLP-1 agonist | Approved |
Retatrutide | GIP/GLP-1/glucagon agonist | Phase 3 |
AOD-9604 | hGH fragment 176-191 | Preclinical |
5-Amino-1MQ | NNMT inhibitor — not a peptide | Preclinical |
This category contains the two best-evidenced compounds on the entire list. Semaglutide and tirzepatide have full labels, large trial programmes and ongoing pharmacovigilance — a different tier of evidence from everything else here.
4. Repair and recovery
Compound | Mechanism | Status |
|---|---|---|
BPC-157 | Pentadecapeptide; rodent tissue repair literature | Preclinical |
TB-500 | Thymosin beta-4 fragment | Preclinical |
Wolverine stack | BPC-157 + TB-500 | Unstudied as a combination |
The BPC-157 rodent literature is genuinely extensive and genuinely rodent. The few human studies are small, and none shows that it works. See the joint pain guide and BPC-157 dosage guide.
5. Sexual health
Compound | Mechanism | Status |
|---|---|---|
Bremelanotide (PT-141) | Melanocortin agonist | Approved as Vyleesi — for premenopausal women |
Melanotan II | Melanocortin agonist | Not approved; subject of FDA warnings |
Oxytocin | Nonapeptide hormone | Approved for obstetric use |
PT-141 is approved, but not for men. Vyleesi’s indication is hypoactive sexual desire disorder in premenopausal women. Use in men is off-label and outside the population the trials studied — an important distinction given how it is marketed. See the PT-141 dosage guide.
How the evidence tiers compare
Tier | Compounds | What exists |
|---|---|---|
Approved drugs | Semaglutide, tirzepatide, tesamorelin, PT-141 | Labels, trials, pharmacovigilance |
Human studies, no approval | Kisspeptin-10, enclomiphene, retatrutide | Published human data |
Preclinical only | BPC-157, TB-500, CJC-1295, ipamorelin, AOD-9604 | Animal or cell culture |
Unstudied combinations | Wolverine stack, KLOW, blends | Component data only |
The gap between the first and third rows is larger than any difference within them. A compound with an approved label and one with a rodent literature are not two points on a scale — they are different kinds of knowledge.
What to establish before anything else
Baseline bloodwork, particularly for anything touching the hormonal axis.
Which tier the compound sits in, using the table above.
Whether it is a peptide at all. MK-677, enclomiphene and 5-Amino-1MQ are not.
Whether an approved alternative exists. For metabolic and GH-axis goals it frequently does, with a label attached. See the FDA-approved peptides list.
A batch-specific COA for anything bought as a research compound.
Research and educational use only. Peptide Library is an independent research and comparison platform and does not sell peptides. Nothing here is medical advice, dosing guidance, or a recommendation to administer any substance to a person or an animal. Consult a licensed clinician for anything concerning human health.
Sources
- 1. Chronic subcutaneous kisspeptin-10 stimulates gonadotropin secretion for 12 days in healthy men — European Journal of Endocrinology (2026) Source PubMed
- 2. Clomiphene or enclomiphene citrate for the treatment of male hypogonadism: a systematic review and meta-analysis of randomized controlled trials — Archives of Endocrinology and Metabolism (2025) Source PubMed
Author
Peptide Library Editorial
Editorial content from Peptide Library. Research and educational use only. Not medical advice.
Related articles
Related peptides
Research smarter with Peptide Library.
Compare peptides, review vendor data, and use research calculators in one place.
Explore the LibraryResearch and educational use only. Not medical advice. Peptide Library does not sell peptides.